ABSTRACT
INTRODUCTION
We assessed the primary and secondary outcomes at 12 months. The t-paired sample test was used to determine statistical significance (https://www.graphpad.com/quickcalcs/ttest1.cfm) . A P value of <0.05 was interpreted as statistically significant.
RESULTS
Ninety-nine aflibercept treated eyes (89 patients) entered the statistical analysis.
Three eyes out of 102 were excluded as they were switched to other treatment over 12 -month follow up period. The mean number of aflibercept injections received was 6.92 ( Figure 1 ). Fourteen percent of included eyes had less than 5 monthly loading doses (minimum 3) due to either clinicians' discretion or patients did not attend or cancelled their appointments. Thirty percent of included eyes did not have further injections after the loading phase. Two patients (two eyes from the cohort) did not complete the follow up of 12 months. 33% of patients were pseudophakic and 67%
were phakic at baseline.
Aflibercept cohort outcomes
At baseline, the mean VA (SD) (Snellen) was 59.7 (16.1) (20/63) ETDRS letters, the mean CFT (SD) was 431 (129) µm whilst the mean MV (SD) was 9.53 (1.79) mm 3 .
( Table 1 ) At 12 months, the mean VA (SD) (Snellen) was 69.6 (15.2) (20/40) ETDRS letters (p < .0001). The mean CFT (SD) was 306 (122) μm (p < .0001) and the mean MV (SD) was 8.43 (1.58) mm 3 (p < .0001) at 12 months. Thirty-three (33.67 %) eyes gained ≥ 15 ETDRS letters at month 12, and 50 (55.55%) eyes had a decrease in CFT of ≥ 100 microns ( Table 2 ). Three (3.06 %) eyes lost ≥ 15 ETDRS letters and 6 (6.66 %) eyes had an increase in CFT of ≥ 100 microns at the end of follow up period. Forty-seven (46.53%) eyes achieved 10 ETDRS letters or more gain at month 12, whilst 5 (4.95%) eyes lost 10 ETDRS letters or more at the end of follow up.
Mean changes and sub-group analysis according to baseline VA and CFT
We calculated the changes in VA, CFT and MV after 12 months. The mean change in VA was + 9.9 ETDRS. The mean change in MV was -1.08 mm 3 whilst the mean change in the CFT was -128 μm.
We sub-divided the included eyes into two subgroups according to the baseline visual acuity; < 69 ETDRS letters (< 20/50 Snellen) and  69 ETDRS letters ( 20/40 Snellen) and according to the baseline CFT; 400-499 microns or  500 microns.
Sixty-six percent of eyes had baseline visual acuity less than 69 ETDRS letters (< 20/50 Snellen). The mean change in visual acuity in the subgroup with baseline VA less than 69 letters (< 20/50 Snellen) was +13.8 ETDRS letters (Figure 2 Real-world results have not displayed the same amount of improvement in visual acuity with anti VEGF treatment in DMO, with the frequency of injections being the factor that tends to be cited in order to explain this finding. (17) There are no largescale real-world data looking at aflibercept therapy for DMO. However, it was previously hypothesised based on diminished number of injections in a real world setting that the results would be inferior to the major trials. Our study is look at real world evidence of aflibercept use and with an average of 6.92 injections, significantly less than the 9-10 observed in DRCR.net protocol T, with around 10 ETDRS letters of improvement noted. In those eyes with VA of less than 69 letters, the improvement in acuity was markedly greater than in those with higher baseline visual acuity scores, thus confirming the ceiling effect seen when treating patients with good initial baseline acuity. The ceiling effect was noted when divided our cohort based on degree of foveal thickening. Our results indicate that despite a significantly lower number of injections over a 12-month period than those observed in the landmark trials, good visual and anatomical outcomes are attainable.
The number of injections was less than those used in the large clinical studies. We believe this is a significant collection of real-world outcomes that show very good results with aflibercept therapy for diabetic macular oedema in a real-world setting.
Regardless to the limitations of this study, which are number of patients included, and lack of more detailed analysis of macular perfusion, we believe that the reporting of real-world outcomes is of benefit to clinicians who are treating patients in the real world, rather than a clinic trial setting and thus do not see this as a limitation.
Real world evidence is important in making decisions about how to treat patients with DMO in an efficient and cost-effective manner. Modern healthcare systems may not be able to provide injections at the same frequency for sustained periods of time as was observed in the major studies. This is the largest published dataset examining aflibercept therapy provided in a real world setting and our observed improvement could potentially be explained in theory by the pharmacokinetic advantages of aflibercept in its increased binding affinity for VEGF, its longer duration of action and ability to bind placental growth factor. Whatever the reason we have demonstrated that it is possible to deliver very good visual acuity and anatomical outcomes in a real-world setting using less injections than those used in the published literature. Diabetic maculopathy is a major cause of sight impairment amongst working age people and the prevalence of type 2 diabetes is rapidly increasing in both the developed and less well-developed world economies. We demonstrate that good outcomes can be achieved in the real world away from clinical trials and this should support doctors and patients together in managing diabetic macular oedema. 
